Edesa Biotech, Inc.
NASDAQ:EDSABiotechnology
Healthcare
$5.75 +1.31%
+$0.09 today
- Market cap
- $55.39M
- Beta
- 1.07
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.27
52W Low $0.72High $20.32
Volume 0.07M
Average 0.62M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$7.91M
FY 2025 · Annual
Net Income
-$7.19M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| Gross Profit | (118.79K) | (118.19K) | (183.47K) | (186.05K) | (119.27K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 17.95M | 13.34M | 4.79M | 2.88M | 3.67M |
| Selling, General & Admin | 5.73M | 5.04M | 4.43M | 4.13M | 4.24M |
| Operating Expenses | 23.68M | 18.37M | 9.22M | 7.01M | 7.79M |
| Depreciation & Amortization | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| EBITDA | (13.22M) | (17.43M) | (8.19M) | (5.98M) | (7.07M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (23.68M) | (18.37M) | (9.22M) | (7.01M) | (7.91M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 11.17K | 64 | 289.85K | 153.5K | 2.56K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 10.34M | 822.67K | 849.14K | 845.5K | 726.84K |
| Income Before Tax | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.18M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 800 | 800 | 800 | 800 | 800 |
| Net Income | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.19M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (7.74) | (8.37) | (2.93) | (1.93) | (1.27) |
| EPS (Diluted) | (7.73) | (8.37) | (2.93) | (1.93) | (1.27) |
| 1.73M | 2.1M | 2.86M | 3.2M | 5.68M | |
| 1.73M | 2.1M | 2.86M | 3.2M | 5.68M |
EDSA Earnings Waterfall · TTM
NASDAQ:EDSA · Revenue to Net Income
Key Ratios
EPS$-1.35
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$10.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.35, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Aug 4, 2026 | |
| EFFECT | EFFECT filing | Jul 13, 2026 | |
| 424B3 | 424B3 filing | Jul 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 2, 2026 | |
| S-3 | S-3 filing | Jul 2, 2026 |
How much revenue does EDSA generate?
Edesa Biotech, Inc. (EDSA) reported $0.00 of revenue in fiscal 2025.
Is EDSA profitable?
Edesa Biotech, Inc. (EDSA) reported -$7.19M of net income.
Continue the stock analysis
Jump to another research area for this company.